Wearside pharmaceutical firm Onyx Scientific invests in new cleanroom suite

New facilities at Sunderland-based Onyx Scientific would help the firm carry out lucrative projects in manufacturing

Denise Bowser, commercial director at Onyx Scientific
Denise Bowser, commercial director at Onyx Scientific

Wearside pharma firm Onyx Scientific is investing in space to carry out potentially lucrative manufacturing projects following rising demand for its small scale services.

The Sunderland-based business is installing a new cleanroom suite at its facility aimed at satisfying demand in specialist GMP (good manufacturing practice) contracts from clients in Europe and the US that are developing new drug products intended for clinical trials.

Onyx Scientific specialises in the production of Active Pharmaceutical Ingredients (API) during clinical development projects for customers – contracts which can then lead to the customers returning and asking them to carry out GMP projects.

Introducing the new GMP suite means the firm, which was established 15 years ago, can potentially grow by taking on more work.

Its expansion plans were given the go-ahead following another successful audit by the Medicines and Healthcare Products Regulatory (MHRA) Agency in February.

Denise Bowser, commercial director at Onyx Scientific, said: “This latest investment will bring the total capacity at our UK site up to four dedicated GMP suites, which represents a steady but significant growth in this area over the past few years.

“We have worked with hundreds of clients at the small scale non-GMP stage and have been able to provide rapid scale up to GMP for many of them with the same technical team, all under one roof.”

“So by having an additional GMP suite at our disposal, it gives us even greater flexibility to assist our clients that are under increasing timeline pressure to deliver against their development programs.”

Driven by market demand, the investment should lead to the creation of several new chemist roles in the future.

Ms Bowser added: “As well as attracting new clients through reputation, we are seeing more existing clients returning for GMP work.

“Often we have supported such clients at an earlier stage in the drug development pipeline and having impressed first time round, they return when they are ready to scale-up for GMP supply.”

Onyx Scientific has achieved preferred partner status and undertaken GMP projects for some of the world’s largest pharmaceutical companies and major institutions such as Cancer Research UK.

The company also works with many specialty drug development firms and biotech organisations across the globe, helping accelerate candidates from discovery to production.

Journalists

David Whetstone
Culture Editor
Graeme Whitfield
Business Editor
Mark Douglas
Newcastle United Editor
Stuart Rayner
Sports Writer